3 completed, 1 terminated. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow TRU 016: new trials by email Literature Review of TRU 016 trials Research Report on TRU 016
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1b Safety and Efficacy Study of TRU-016 20 mg/kg TRU-016 + Rituximab, 10 mg/kg TRU-016 + Rituximab, TRU-016 20 mg/kg + Obinutuzumab - Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma | Phase 1 | Terminated | Aptevo Therapeutics | 87 | 2012-09-01 | 2021-05-20 |
| A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma TRU-016, Bendamustine, Rituximab - B-cell Small Lymphocytic Lymphoma Recurrent | Phase 1 | Completed | Aptevo Therapeutics | 12 | 2011-05-01 | 2017-06-28 |
| Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia TRU-016 and bendamustine, Bendamustine, 15 mg/kg TRU-016 and bendamustine - Chronic Lymphocytic Leukemia (CLL) | Phase 1 / Phase 2 | Completed | Aptevo Therapeutics | 79 | 2010-09-01 | 2021-06-10 |
| Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma TRU-016 (anti-CD37 protein therapeutic) - Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) | Phase 1 | Completed | Aptevo Therapeutics | 96 | 2008-01-01 | 2017-06-28 |
Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, Non-Hodgkin (2) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, T-Cell, Peripheral (1)
United States (4) · Austria (1) · Germany (1) · Poland (1) · Spain (1)
Scott Stromatt, MD (3) · Scott C. Stromatt, M.D. (1)